Ensysce Biosciences Reports First Quarter 2026 Financial Results
Ensysce reported Q1 2026 results with a net loss of $3.6 million and cash reserves of $0.7 million, highlighting a critical need for capital despite a recent $2 million financing close. Clinically, the company secured IRB approval to initiate Part 3 of the PF614-MPAR-102 study, the final stage evaluating its overdose-protection technology, and published peer-reviewed data validating the MPAR mechanism.
Key figures
- Revenue
- 0
- Ga expenses
- 1176348
- Rd expenses
- 3346881
- Federal grants
- 960999
- Cash and equivalents
- 745482
- Recent financing tranche
- 2000000
- Total financing commitment
- 20000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.